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ABSTRACT 
 
The attachment of ubiquitin to substrate proteins is a key process in regulating 
cellular events such as cell cycle progression, signal transduction, differentiation, 
apoptosis, and the clearance of misfolded or aberrant proteins. Like other post-
translational modifications, ubiquitination is also reversible. Deconjugation is 
performed by a family of cysteine- or metallo-proteases collectively known as 
deubiquitinating enzymes (DUBs). Approximately 100 putative DUBs have been 
identified in the human genome but only a minority of them has been functionally 
characterized. The aim of this thesis has been to study the function of selected 
DUBs in disease-relevant cellular pathways.  
 
Screen of the canonical Wnt-signaling pathway with an RNA interference (RNAi) 
library targeting the human DUBs identified the ubiquitin-specific protease (USP)-4 
as a negative regulator. USP4 interacts with two known components in the pathway: 
the Nemo like kinase (Nlk) and the T-cell factor 4 (TCF4). NLK promotes nuclear 
accumulation of USP4 where a subpopulation of TCF4 is a substrate of USP4-
dependent deubiquitination. Using a yeast-2 hybrid strategy to search for relevant 
interactions, we identified the proteasome as a binding partner of USP4. USP4 
interacts with the S9 subunit of the 19S regulatory particle (RP) through an N-
terminal ubiquitin-like (UBL) domain that resembles, but is functionally distinct 
from, the UBLs of hHR23a/b and Ubiquilin-1. S9 is as an essential proteasome 
subunit that may regulate the structural integrity of the 26S complex. Thus, USP4 
may play a role in the dynamics of ubiquitination at the proteasome. 
 
A bioinformatics strategy was used to search for membrane-associated DUBs. We 
found that a putative transmembrane domain targets USP19 to the endoplasmic 
reticulum (ER). USP19 is a target of the unfolded protein response and rescues 
ERAD substrate from proteasomal degradation. Moreover, USP19 interacts with the 
E3 ligases seven in absentia homolog (SIAH) 1 and SIAH2 that mediate USP19 
ubiquitination and degradation by the proteasome. Bioinformatics and biochemical 
analysis revealed the presence in USP19 of a SIAH-interacting motif that is found 
in a subset of SIAH targets and may function as a degradation signal. A non-
enzymatic role of USP19 in the regulation of the reposed to hypoxia was suggested 
by the finding that wild-type and catalytic mutant USP19 interact with the hypoxia-
inducible factor-1α (HIF-1α). In the absence of USP19, cells fail to mount a proper 
response to hypoxia.  
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1 INTRODUCTION 
 
1.1 General introduction 
 
Already in the late 1930s, Rudolph Schoenheimer suggested that the cellular pool of 
proteins is in a “dynamic state” involving constant synthesis and degradation [1]. 
We now know that the ubiquitin-proteasome system (UPS) plays a key role in 
protein degradation and in the regulation of cellular homeostasis.  
 
Protein ubiquitination was discovered in the early 1980s as a post-translational 
modification involving covalent attachment of ubiquitin, a 76 amino acid long 
polypeptide highly conserved from yeast to mammals, to a lysine residue of the 
substrate [2].  
 
The components of the UPS include, in addition to ubiquitin, a family of enzymes 
that activate (E1), conjugate (E2), and ligate ubiquitin to the substrate (E3), and the 
proteasome that degrades the ubiquitinated proteins. Ubiquitin is conjugated to the 
substrates via its C-terminal glycine residue with the help of the E1, E2 and E3 
enzymes in a sequential manner. Once the first ubiquitin is added to the substrate, 
the procedure is repeated to attach more ubiquitin to the previous ubiquitin finally 
forming a polyubiquitin chain [3]. The poly-ubiquitinated substrates bound to the 
proteasome are subject to deubiquitination by DUBs, then unfolded and 
translocated into the inner proteolytic chamber of the proteasome where they can be 
degraded into small peptides (Figure 1). 
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Figure 1. Overview of the ubiquitin-proteasome system  
Ubiquitin conjugates to the substrates via its C-terminal glycine residue by the help of the 
E1, E2 and E3 enzymes. Once the first ubiquitin is added to the substrate, the procedure is 
repeated, forming a polyubiquitin chain. The poly-ubiquitinated substrate binds to the 
proteasome where it is deubiquitinated by DUBs, unfolded and translocated into the inner 
proteolytic chamber for degradation into small peptides. 
 
The UPS plays diverse roles in cellular processes. First, the system controls the 
degradation of many key proteins involved in cellular events such as cell cycle 
progression, apoptosis, development and transcription. Second, the UPS plays a role 
in the immune response since the majority of peptides presented by the major 
histocompatibility complex (MHC) class I is generated by the proteasome. Last, the 
UPS has a crucial function in the clearance of aberrant and misfolded proteins. In 
different cellular stress situation, the UPS protects the cell from toxic accumulation 
of misfolded and damaged proteins. In addition, the UPS has non-proteolytic roles 
such as DNA repair, chromatin-remodeling, membrane trafficking, transcription 
and signaling [4].  
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1.2 Ubiquitin-mediated signaling  
 
1.2.1  Ubiquitin and ubiquitin-like proteins 
 
Ubiquitin is encoded by a gene family that contains monomeric and multimeric 
ubiquitin genes [5]. The monomeric ubiquitin genes are C-terminally linked to 
ribosomal proteins. The multimeric ubiquitin genes encode head to tail ubiquitin 
precursors. The ubiquitin C-terminal hydrolases (UCH) cleave both forms of 
precursors in the C-terminal Gly residue, forming functional ubiquitin monomers. 
The crystal structure of ubiquitin shows a distinctive fold characterized by a β-sheet 
with five antiparallel β-strands, a single helix on top and an exposed C-terminal tail, 
which is important for conjugation [6]. Ubiquitin is highly expressed in cells and is 
very stable; it is continuously recycled after tagging protein for degradation.  
 
Ubiquitin-like proteins comprise a group of proteins that share structural similarities 
with ubiquitin. They can be divided into two groups 1) the ubiquitin-like modifiers 
(UBLs) and 2) proteins containing ubiquitin-like domain [7]. UBLs such as the 
small ubiquitin-related modifier (SUMO), the neural precursor cell expressed, 
developmentally down-regulated 8 (Nedd8) and the interferon-stimulated gene 15 
(ISG15) are conjugated to substrates in a process similar to ubiquitination. 
Modification by UBLs has diverse roles in cellular processes such as DNA repair, 
protein trafficking and signal activation [8-10]. The proteins containing ubiquitin-
like domains play roles in different cellular events and some of them interact with 
the proteasome.  
 
1.2.2  Ubiquitination  
 
Ubiquitination occurs via attachment of the C-terminal Gly of ubiquitin to a Lys 
residue, or less commonly to the N-terminus, of the substrate. The process is 
mediated by the sequential action of three enzymes: the ubiquitin activating enzyme 
(E1), the ubiquitin-conjugating enzyme (E2) and the ubiquitin ligase (E3). The first, 
ubiquitin is activated by the formation of a thiol linkage between its C-terminal Gly 
and a Cys residue in the E1 enzyme. This first step requires the hydrolysis of ATP. 
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Then, the activated ubiquitin is transferred to a Cys residue of an E2 enzyme. In the 
third step an E3 ligase catalyzes the transfer of ubiquitin from the E2 to a Lys 
residue of the target protein [11]. Once the first ubiquitin is added to the substrate, 
the procedure is repeated to attach more ubiquitin to the previous ubiquitin forming 
a polyubiquitin chain [11]. 
 
The human genome encodes two E1 [12], dozens of E2 enzyme and more than 1000 
E3 ligase [13]. The E3 ubiquitin ligases determine substrate specificity through 
recognition of degradation signals, also called degrons, which are domains or small 
motifs present in the substrate [14].  
 
The E3 ubiquitin ligases can be divided into four groups based on their structure 
and ubiquitination mechanism: the HECT (Homolog of E6-AP C-terminus) E3s, 
RING (Really Interesting New Gene) domain E3, PHD domain E3s and U-box-type 
E3s. The HECT E3 and RING domain E3 are two big group of E3 ligases, they 
regulate diverse cellular events such as cell proliferation, cell cycle arrest and 
apoptosis [15].The HECT E3 first loads the ubiquitin from the E2 to an internal Cys 
residue at the C-terminus of the HECT domain, then passes the ubiquitin to the 
targeted protein [16]. The RING domain E3 acts like scaffolds that bind the E2 
conjugating enzyme via the RING domain, promoting the transfer of ubiquitin 
directly from the E2 to the substrate [17].   
 
1.2.3 Functions of Ubiquitination 
 
The combination of E2 and E3 enzymes determine the type of ubiquitin chain 
linkage that will be generated [18]. Proteins can be mono-ubiquitinated in one or 
multiple Lys residues. Ubiquitin chains can be formed on each of the seven Lys 
residues of ubiquitin at position 6, 11, 27, 29, 33, 48 and 63 [19]. A very important 
functions of ubiquitination is to serve as signal for proteasomal degradation [19] but 
ubiqutination also has diverse non proteolytic functions, including the regulation of 
protein-protein interactions and subcellular localization [20,21].  
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Lys48 linked chains are the most abundant ubiquitin chain type in human cells 
(28%) [19]. Lys48 chain ubiquitinated substrates are degraded by the proteasome 
while ubiquitin itself is recycled through the activity of deubiquitinating enzymes 
(DUB). Lys11 ubiquitin chains may also serve as a degradation signal [22,23]. For 
example, this type of linkage plays an important role in endoplasmic-reticulum-
associated degradation (ERAD) [22]. Lys63 ubiquitin chains serve mainly non-
proteolytic roles in transcription, intracellular protein trafficking, autophagy, DNA-
damage response and cell signaling [24-27].  
 
 
 
1.3 The proteasome  
 
1.3.1  The 26S proteasome 
 
The proteasome is responsible for selective protein degradation in eukaryotic cells 
[28], and accounts for approximately to 1% of cellular protein content [29]. The 
26S proteasome is a 2.5 MD protein complex composed of more than 30 subunits 
[28]. It can be divided into two smaller sub-complexes, the 20S core particle (CP) 
and the 19S regulatory particle (RP) The 19S RP can bind the 20S CP at one or at 
both ends [29] (Figure 2).  
 
 
 
Figure 2.  Schematic diagram of the 26S proteasome 
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The 26S proteasome contains the 20S core particle (CP) and the 19S regulatory particle 
(RP). The CP is composed of four heteroheptameric rings, two outer α rings and two inner 
β rings that harbor the catalytic activities. The RP can be divided into the lid and base sub-
complexes. 
 
The CP is a barrel-shaped structure that consists of four stacked rings, two outer α-
rings and two inner β-rings (α1-7-β1-7-α1-7-β1-7). The proteolytic active sites are 
in the two identical -rings. The 1 subunit is a protease with caspase-like activity, 
which cleaves after acidic amino acids. The β2 subunit has trypsin-like activity, 
cutting after basic residues and the β5 subunit possesses chymotrypsin-like activity 
and prefers to cleave after hydrophobic amino acids [30]. The combination of three 
different activity sites is essential for degrading a large variety of peptide sequences 
and also for high efficiency in protein degradation [31]. 
 
1.3.2  The 19S regulatory particle 
 
The 19S RP has multiple roles in regulating the activity of the proteasome including 
ubiquitin chain remodeling and deubiquitination, substrate unfolding and 
translocation into the 20S catalytic chamber [32]. The 19S RP is composed of at 
least 19 subunits and can be divided into two sub-complex: the base and the lid.  
 
The base contains six AAA ATPases that form a ring structure, the Rpt1/S7, 
Rpt2/S4, Rpt3/S6, Rpt4/S10b, Rpt5/S6 and Rpt6/S8 [32]. In addition, the base also 
contains four non-ATPase subunits: Rpn1/S2, Rpn2/S1, Rpn10/S5a and 
Rpn13/hRpn13 [33-36]. The ATPases are believed to play an important role in 
substrate unfolding and thereby assists the translocation of the substrate into the 
catalytic chamber [32]. One ATPases, Rpt2/S4 is reported to have a role in opening 
the pore into the 20S CP [37,38]. Another ATPases, Rpt5/S6 is known to play a role 
in recognizing poly-ubiquitin chains in an ATP dependent manner [39]. Rpn1/S2 
and Rpn2/S1 are the largest subunits of the proteasome. They were predicted to 
form a scaffold or platform unit providing binding capacity to proteasome 
interacting proteins [40,41]. Rpn1/S2 is known to bind ubiquitin receptor proteins 
like Rad23, Dsk2 and Ddil. Most of those ubiquitin receptor proteins belong to the 
UBL-UBA family. They contain a UBL domain that can interact with Rpn1 in the 
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proteasome, and one or more UBA domains that bind to poly-ubiquitinated chains 
[42]. These proteins have been proposed to function as shuttling factors that 
selectively deliver poly-ubiquitinated substrates to the proteasome [43]. Rpn10/S5a 
and Rpn13/hRpn13 are two well-studied ubiquitin receptors that bind ubiquitin 
chains [44,45]. 
 
The lid is composed of 8 subunits that can be divided into two groups based on their 
domain structure: Rpn3/S3, Rpn5, Rpn6/S9, Rpn7/S10a, Rpn9/S11 and Rpn12/S14 
are predicted to share a PCI domain in their C-terminal, Rpn8/S12 and Rpn11/S13 
have a MPN domain in common [46]. Rpn6/S9 is an essential component of the 
26S proteasome. Yeast studies show that Rpn6 localizes at the outer rim of lid 
particle and forms a protrusion reaching down to the ATPases and alpha rings in the 
20S RP, functioning thereby as a molecular clamp that holds the 19S RP and the 
20S core together [47]. Conditional knock-out of Rpn6 in S. cerevisiae impairs the 
assembly of proteasome thus affecting proteasome activity [46]. 
 
One of the major tasks of the 19S RP is to remove the poly-ubiquitin chains from 
the substrate by cleavage of the isopeptide bond between the substrate and the first 
ubiquitin in the chain to release the whole chain [45,48]. Rpn11/S13 is the essential 
DUB responsible for this function [45,48,49]. Two additional DUBs associated with 
the proteasome participate the deubiquitination process, UCH37/UCHL5 and 
Ubp6/USP14 [50-52]. While Rpn11/S13 promotes substrate degradation, 
UCH37/UCHL5 and Ubp6/USP14 antagonize substrate degradation  [53]. These 
DUBs trim the poly-ubiquitin chain from the distal end. Thus, the longer the chain, 
the stronger of the interaction of the substrate with the proteasome. By trimming the 
ubiquitin chain, these DUBs regulate the time of substrate-proteasome interaction 
thus determining the rate of degradation [50].  
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1.4 Deubiquitination 
  
1.4.1 Deubiquitinating enzyme 
 
Protein modification by ubiquitin is a dynamic and reversible process. The 
conjugated polyubiquitin chains are removed and disassembled by a group of 
proteins called DUBs. DUBs are important regulators of diverse cellular processes, 
such as the cell-cycle, DNA repair and chromatin remodeling. The human genome 
encodes approximately 100 DUBs that can be divided into six subfamilies: the 
ubiquitin C-terminal hydrolases (UCHs), ubiquitin-specific proteases (USPs), 
ovarian tumor proteases (OTUs), Machado-Joseph disease protein domain proteases, 
JAMM/MPN domain-associated metallopeptidases (JAMMs) and monocyte 
chemotactic protein-induced protein (MCPIP) families [54]. They are Cysteine 
proteases, except for the JAMM/MPN+ DUBs, which are Zinc metalloproteases.  
 
DUBs have different functions in the UPS [55,56], including: (1) Ubiquitin 
precursor processing. DUBs can cleave ubiquitin precursors consisting of multiple 
ubiquitins formed as tandem repeats or ubiquitin fused to the N-terminus of the L40 
and S27 ribosomal proteins [4]; (2) Ubiquitin recycling. DUBs can trim the 
ubiquitin chain from a substrate prior to degradation. The cleaved off ubiquitin 
chain will be further disassembled so that recycled ubiquitin re-enter the cellular 
ubiquitin pool. This trimming of ubiquitin chains on substrates is also essential for 
(3) the regulation of protein stability. Ubiquitination serves as triggering signal for 
protein degradation. By trimming ubiquitin chain on a substrate, DUB regulates 
protein stability. For example, USP10 and USP7 regulate p53 stability via their 
deubiquitinating activity [57-59]. (4) Non-degradation ubiquitin signal regulation. 
For example, USP4 removes Lys63 linked polyubiquitin chains from TAK1, which 
leads to its inactivation and down regulation of NF-B activation [60]. 
 
DUBs can be regulated at different levels. Including: 1) Transcription level; For 
example: the protein causing cylindromatosis (turban tumor syndrome), also known 
as CYLD, is induced by activation of the NF-B pathway [61]; 2) Post-translational 
modification. Phosphorylation or ubiquitin-like modifications can regulate DUB 
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activity. For example, phosphorylation of CYLD inhibits its ability to 
deubiquitinate the TNF receptor-associated factor-2 (TRAF2), thus leading to 
suppression of the NF-B pathway [62]; 3) Protein binding partners and allosteric 
regulation. For example, USP1 shows 35-fold higher activity when bound to UAF1 
(USP1-associated Factor 1) [63]. Upon binding to the proteasome, USP14 and 
UCH37 display hundred folds increased activity [51,64-67]; 4) Degradation. USP20 
is ubiquitinated by the E3 ligase pVHL and degraded by proteasome [68]. 
 
1.4.2   USP4  
 
USP4 was discovered in the early 1990’s in a search for genes located near the 
Monkeypox virus  20 retroviral insertion site [69]. It was originally called UNP, for 
ubiquitous nuclear protein, and changed to the new systematic nomenclature for 
human ubiquitin specific proteases in 1999 [70]. USP4 RNA levels are elevated in 
several types of human cancers and overexpression of USP4 cDNA leads to 
oncogenic transformation in NIH 3T3 cells [71,72]. USP4 has regulatory functions 
in different signaling pathways. By deubiquitinating TRAF2, TARF6 and TAK 
(transforming growth factor--activated kinase)-1, USP4 inhibits the TNF induced 
activation of NF-κB [60,73,74]. Recent work implicates USP4, as an inducer of 
TGF-β signaling via direct interaction and deubiquitination of the TGF-β receptor 
type I (TβRI). Furthermore, USP4 inhibits p53 through deubiquitination and 
stabilization of ARF-BP1 (ARF-binding protein-1), an E3 ligase for p53 [72]. 
Additional interacting partners of USP4 include Ro52, retinoblastoma protein and 
the A(2A) adenosine receptor [75-80]. 
 
USP4 is 936 amino acids long and contains two UBL domains, one in N-terminal 
next to DUSP domain and one in the middle of the protein, near the catalytic 
Cys residue. It has been reported that the UBL domain in the middle of USP4 
inhibits the deubiquitinating activity [81] (Figure 3). 
 
 
Figure 3. Schematic illustration of USP4  
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USP4 contains a conserved DUSP domain and two UBL domains. The Cys and His box in 
the DUB domain form the catalytic active site. 
 
1.4.3  USP19 
 
USP19 was first identified in a screen for DUBs expressed in rat skeletal muscle 
[82]. USP19 is phylogenetically conserved. Human USP19 has 81% and 95% 
amino acid identity with rat and mouse USP19 respectively [82]. It has been 
reported that USP19 plays a positive role in G1/S transition, by binding and 
stabilizing KPC1, a ubiquitin ligase for p27. Cells depleted of USP19 show reduced 
growth rate [83,84]. USP19 has also been shown to stabilize c-IAPs (the inhibitor of 
apoptosis) with consequent inhibition of apoptosis [85].  
 
USP19 is 1357 amino acids long [82]. The USP domain is in the middle of the 
protein that also contains a Zn-MYND (myeloid translocation protein 8, Nervy and 
Deaf1) domain that may mediate protein-protein interaction [86,87]. In the N-
terminal of the protein, there are two p23-like domains that suggest chaperon 
functions [88]. The C-terminal transmembrane domain (TMD) is responsible for ER 
anchoring [89] (Figure 4). 
 
Figure 4. Schematic illustration of USP19  
USP19 contains two p23-like domains, a Zn-MYND domain and a C-terminal 
transmembrane domain (TMD). The Cys and His box in the USP domain form the catalytic 
active site.  
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1.5 Regulation of cellular functions by deubiquitination  
    
1.5.1   Wnt-signaling  
 
The Wnt signaling pathway regulates a vast array of cellular process such as stem 
cell maintenance, tissue polarity, cell proliferation and movements [90]. The Wnt 
pathway is conserved in many species from C. elegans, Drosophila, Xenopus to 
mammals. Deregulation of Wnt pathway is associated with many hereditary 
disorders, cancer and other diseases [91]. Mutations in Wnt pathway can be found 
in various types of cancers such as gastric cancer, colon cancer and breast cancer 
[91]. Upon ligand binding, different downstream signaling pathways can be 
activated: the canonical Wnt/-catenin pathway, the non-canonical planar cell 
polarity (PCP) pathway or the Wnt/Ca2 pathway [92].  
 
1.5.1.1  The canonical Wnt/-catenin pathway 
Among the three Wnt pathways, the canonical Wnt/-catenin pathway is the best 
studied. The first step of activation is the binding of the ligand to receptors. Two 
types of receptor families have important role in Wnt/-catenin pathway activation: 
the frizzled (Fz) seven-pass transmembrane receptors [91], and the LDL receptor-
related proteins 5 and 6 [93]. LRP5/6 receptors function with neighboring Fz 
receptor to form ternary complexes with Wnt ligand [94]. As the key transcriptional 
activator in the pathway, the cellular level of -catenin is tightly regulated. It should 
be noticed that -catenin, is also a component of adherent junctions, where it plays 
an important role as binding partner for the cytoplasmic tail of different cadherins 
[91]. 
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Figure  9.  Overview of the canonical Wnt/-catenin pathway  
A) In the absence of Wnt, -catenin forms a complex with Axin, APC, GSK3 and CK1 and 
is phosphorylated by GSK3 and CK1. The phosphorylated -catenin is recognized and 
ubiquitinated by the E3 ligase -TrCP, leading to its proteasomal degradation. B) In the 
presence of Wnt, Wnt forms a receptor complex with Fz and LRP5/6. The formation of the 
complex recruits the scaffold protein Dishevelled (Dvl) and leads to LRP phosphorylation. 
Then Axin is recruited to the LRP5/6, resulting in dissociation of the destruction complex. 
-catenin accumulates and translocates to the nucleus where it serves as a transcriptional  
co-activator for TCF to activate Wnt responsive gene. (Figure adopted from Dev Cell. 2009 
Jul;17(1):9-26) 
 
When Wnt receptor complexes are not bound by a ligand, the cytoplasmic -catenin 
is captured by a destruction complex that consists of Axin, the tumor suppressor 
adenomatous polyposis coli gene product (APC), casein kinase 1 (CK1), and 
glycogen synthase kinase 3 (GSK3) [93]. The scaffolding protein Axin provides 
binding sites for -catenin CK1, GSK3 and APC. CK1 and GSK3 sequentially 
phosphorylate -catenin promoting its interaction with the ubiquitin E3 ligase β-
TrCP, leading to ubiquitination and degradation by the proteasome [93]. The 
continuous degradation prevents -catenin from going into the nucleus with 
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consequent repression of Wnt target genes by DNA-bound T cell factor (TCF) [95] 
(Figure 9).  
 
The canonical Wnt/-catenin pathway is activated when a ligand binds to its Fz 
receptor and its co-receptor LRP5/6. The formation of the complex recruits the 
scaffold protein Dishevelled (Dvl) and leads to LRP phosphorylation. Then Axin is 
recruited to the LRP5/6, resulting in dissociation of the destruction complex. 
Unmodified form of -catenin cannot be recognized by -TrCP thus leading β-
catenin accumulation and subsequent translocation to the nucleus [91]. In the 
nucleus, -catenin interacts with transcription factor TCF either by replacing the 
repressors binding to TCF or by directly binding to TCF. TCF and β-catenin 
together activate Wnt gene expression [96] (Figure 9). More than 100 direct target 
genes have been identified, many of them are important regulators of cell cycle 
progression, determination of cell fate and differentiation [91] 
 
1.5.1.2 Regulation of Wnt signaling by deubiquitinating enzymes  
 
Deubiquitination is an important step in regulating the Wnt pathway. Several DUBs 
have been reported to have regulatory functions: 1) Trabid belongs to the OTU 
family of DUBs and was found to be a positive regulator of the Wnt pathway [97]. 
Trabid interacts with APC and regulates the stability of Lys63-linked ubiquitin chains. 
Knock-down of Trabid leads to hyper-ubiquitination of APC, suggesting a negative 
role of Lys63-linked ubiquitination of APC in TCF/LEF mediated gene transcription 
[97]; 2) USP15, a component of the COP9 signalosome (CSN), mediates 
deubiquitination and stabilization of APC thus stimulating the degradation of -
catenin [98]; 3) CYLD was identified as a negative regulator of the Wnt signaling 
pathway as CYLD interacts with and regulates Lys63-linked ubiquitination of Dvl 
[99,100]. Loss of CYLD enhances the Wnt/-catenin pathway [99,100]; 4) UBPY 
belongs to the USP family of DUBs. By suppressing the Fz receptor 
trafficking/degradation, UBPY facilitates the Wnt/-catenin pathway. Gain and loss 
of UBPY function led to up and down regulation of the Wnt/-catenin pathway [101]. 
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1.5.2  ERAD 
 
The ER is the place where newly synthesized secretory or membrane proteins are 
folded with the help of molecular chaperones [102]. In the ER, proteins undergo co- 
and post-translational modifications such as disulfide bond formation and N-linked 
glycosylation, which are important for proper protein folding. The ER has a 
sophisticated quality control system. Only properly folded proteins can pass the 
quality check and be transported out of the ER.  
 
Several DUBs were shown to play a role in ERAD. The otubain YOD1 associates 
with p97 and serve as a p97-associated ubiquitin processing factor in substrate 
dislocation from the ER [103]. Expression of a catalytically inactive form of YOD1 
hampers the dislocation and promotes the stabilization of ERAD substrates [103]. 
Another DUB, Ataxin-3 also binds to p97 and regulates retrotranslocation of ERAD 
substrates. Binding of Ataxin-3 to p97 decreases its interaction with UFD1 and 
poly-ubiquitin chains, thus hampering the retrotranslocation of substrates from the 
ER [104].  
 
 
Figure 5. The ER stress response  
Accumulation of unfolded or misfolded protein in the ER causes ER stress. Cells coping 
with ER stress by: 1) translational attenuation; 2) expression of ER chaperons; 3) 
enhanced ERAD; 4) apoptosis  
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Physiological and pathologic conditions, such as ER calcium depletion, hypoxia or 
energy perturbation can cause the accumulation of unfolded or misfolded proteins. 
This is referred to as “ER-stress”. To deal with this stress situation, the cells activate 
a complex signaling cascade known as the unfolded protein response (UPR), which 
aims to resolve the situation by attenuating further protein synthesis, and by up-
regulating the expression of ER chaperones, to help protein folding, and ERAD 
components, to get rid of terminally misfolded proteins (Figure 5). Under severe 
stress conditions, when the situation cannot be resolved, prolonged UPR signaling 
will eventually trigger apoptosis [105-108] (Figure 6). Three UPR signal pathways 
are initiated by three ER-localized stress sensors:  inositol-requiring protein 1α 
(IRE1α), protein kinase RNA-like endoplasmic reticulum kinase (PERK) and 
activating transcription factor-6 (ATF6). In normal conditions, the sensor proteins 
are inactivated by binding to the ER chaperone binding immunoglobulin protein 
(BiP) [109]. In ER stress situations, BiP binds to the unfolded or misfolded proteins 
thus releasing the sensor proteins, which activates the UPR signaling cascade [109].  
 
 
Figure 6. The UPR signaling pathway.  
Under ER stress, three ER stress sensors IRE1α, PERK and ATF6 are activated to regulate 
the transcriptional and translational program to protect the cell from stress.  
 
 
1.5.3 The response to hypoxia 
 
Oxygen is required for most organisms including bacteria, yeast, invertebrates and 
vertebrates to produce energy. Cells use O2 for mitochondrial ATP generation and 
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also as electron acceptor in metabolism. Since it is very important to keep a good 
balance between oxygen supply and consumption, cells have developed a variety of 
ways to keep oxygen homeostasis. 
 
1.5.3.1 Hypoxia  
 
Hypoxia is a situation when O2 levels drop below a critical threshold, which hinders 
the normal function of organs and cellular signaling pathways [110]. Under hypoxic 
conditions, organs undergo a series of changes to regain O2 homeostasis to limit the 
damage caused by low O2 levels. At the cellular level, various stress proteins are 
expressed to adapt to the low O2 level and switch from aerobic metabolism to 
anaerobic glycolysis.  
 
The hypoxia-inducible factor-1 (HIF-1) transcription factor is a master regulator of 
the hypoxic response via transcriptional activation of more than 100 genes 
important for the cellular adaptation to hypoxia [111]. HIF target genes are involved 
in the regulation of diverse events, such as oxygen transport, iron metabolism, 
glycolysis, glucose transport, cell survival and proliferation, angiogenesis, invasion 
and metastasis [112]. HIF-1 activity is deregulated in many cancers where HIF-1α 
is often overexpressed. Overexpression of HIF-1α is associated with increased 
vascular density, tumor progression and resistance treatment [113]. HIF-1 is a 
heterodimer consisting of a strictly regulated  subunit and a constitutively 
expressed β subunit [114]. Three isoforms of the  subunit have been identified: 
HIF-1, HIF-2 and HIF-3, of which HIF-1 and HIF-2 are the best 
characterized. The role of HIF-3 in hypoxic regulation of gene express is not well 
understood. All of the HIF subunits belong to the family of the basic helix-loop-
helix (bHLH) and PER-ARNT-SIM (PAS) domain containing transcription factors 
[114]. HIF-1 contains four functional domains: the bHLH domain, PAS domain, 
O2-dependent degradation domain (ODD) and transactivation domain (TAD). The 
bHLH and PAS domains are responsible for DNA binding and subunit dimerization. 
It has also been reported that the PAS domain might be responsible for protein-
protein interaction [115]. The ODD domain controls the proteasomal degradation of 
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HIF. The two TAD domains (N-TAD and C-TAD) of HIF-1 mediate the 
transcriptional activation of HIF targeted genes.  
 
1.5.3.2  Regulation of HIF-1 stability  
 
In order to respond to changes in cellular O2 levels, HIF-1 undergoes tight post-
translational regulations. HIF-1 is constitutively expressed but the protein levels 
are kept low by proteasomal degradation [116]. In hypoxic conditions, HIF-1 
starts to accumulate.  
 
Under aerobic conditions, HIF-1 is hydroxylated by specific prolyl hydroxylases 
(PHD1, PHD2 and PHD3) at two conserved proline residues (Pro402 and Pro564) 
in the ODD domain [117,118]. Oxygen is required for this hydroxylation step. The 
hydroxylated protein is recognized by the substrate adaptor subunit of an E3 ligase 
complex, the von Hippel-Lindau tumor suppressor protein (pVHL). The VHL 
ubiquitin ligase, which is a member of the SCF family 
of ubiquitin ligase complexes, includes the subunits pVHL, elongin C, elongin B, 
cullin-2 and Rbx1. Together with the E2 enzyme UbcH5, the VHL ligase stimulates 
HIF-1 poly-ubiquitination and subsequent degradation by the 26S proteasome 
[119-121] (Figure 7).   
 
During hypoxia, the low O2 levels inhibit the activity of PHDs, resulting in HIF-1 
stabilization. The stabilized HIF-1 is then translocated into the nucleus and 
dimerizes with the HIF-1β subunit. With co-activators such as p300, the HIF 
heterodimer binds to a hypoxia responsive element (HRE) in the promoter region of 
the target genes to activate transcription (Figure 7).  
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Figure7. Oxygen dependent regulation of HIF-1stability  
Under normal conditions, HIF-1 is hydroxylated by PHDs, which leads to binding of the 
pVHL E3 ubiquitin ligase complex. The pVHL E3 complex ubiquitinates HIF-1, thus 
resulting its degradation by the proteasome. Under hypoxic conditions, the activity of 
PHDs is inhibited, resulting in the stabilization of HIF-1. HIF-1translocatesto the 
nucleus and dimerizes with HIF-1β. With co-activators such as p300, HIF binds to the 
hypoxia responsive element (HRE) and activates the transcription of target genes. 
 
HIF-1 stability is also regulated by different O2-independent molecular pathways 
involving for example Rack1 and Hsp90 (Figure 8). 
 
Receptor for Activated PKC kinase 1 (RACK1) is a multifunctional scaffold protein 
that plays important roles in different signaling pathways [115]. Overexpression of 
RACK1 promotes HIF-1 degradation independent of cellular O2 level or VHL 
binding whereas knockdown of Rack1 leads to HIF-1 stabilization and activation 
of HIF-1 target genes [115]. With the help of Spermidine/spermine N(1)-
acetyltransferase 1 (SSAT1) Rack1 binds to the PAS-A domain of HIF-1, which 
enables the recruitment of elongin-C and elongin-B thereby promoting HIF-1 
degradation [115,122].  
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The molecular chaperon heat shock protein 90 (HSP90) stabilizes HIF-1 by 
competing with Rack1 for binding to bHLH-PAS domain of HIF-1 [122]. 
 
 
 
Figure 8. O2 dependent and O2 independent regulation of HIF-1α stability  
In the O2 independent pathway, HSP90 and RACK1 compete for binding to the PAS domain 
of HIF-1. HSP90 binding stabilizes HIF-1whereas binding of RACK1 recruits other 
subunits of the E3 ubiquitin ligase complex and induces degradation by the 26S proteasome. 
In the O2 dependent pathway, HIF-1 is hydroxylated by PHDs, which promotes binding of 
the pVHL E3 ubiquitin ligase complex. The pVHL E3 complex ubiquitinate HIF-1and 
induces degradation by the proteasome. (figure adopted from Cell Cycle. 2007 Mar 
15;6(6):656-9.) 
 
1.5.3.3 Regulation of HIF-1 by deubiquitination  
The ubiquitination of HIF-1 is regulated by DUBs. USP20 (also known as VDU2) 
is the first DUB implicated in the regulation of HIF-1 stability [68]. USP20 binds 
and deubiquitinates HIF-1, which results in stabilization and increase the 
expression of HIF-1  targeted genes [68]. The pVHL complex can ubiquinate 
USP20 and cause its proteasomal degradation. Thus, the cellular levels of HIF-1  
  
20 
appear to be dependent on the balance of its ubiquitination and deubiquitination 
[68,123]. The relevance of this mode of HIF regulation is not yet understood.  
 
Aside from ubiquitination/ deubiquitination, phosphorylation, SUMOylation as well 
as subcellualr localization, are also involved in the regulation of HIF-1 [124-128]. 
However, considering the fact of the various regulation pathways through complex 
biological mechanisms, this thesis only focus on the role of ubiquitination/ 
deubiquitination and its following effects on the regulation of HIF-1a. 
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2 Aims of this investigation 
 
The overall aim of this study was to investigate the function of selected DUBs in 
the regulation of disease-relevant cellular functions. To this end my colleagues and 
I have pursued the following specific aims: 
 
 
 
1. Identify new DUBs regulating Wnt pathway and characterize their interaction 
partners and role in signaling. 
 
 
 
2. Identify membrane associated DUBs and characterize their interaction partners 
and involvement in the cellular response to stress. 
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3 Methodology 
 
This section describes the major methodology used in this thesis. A detailed 
description of material and methods is presented in the appended papers. 
 
3.1 RNAi screening 
 
RNA interference (RNAi) is a technique that allows to inhibit the activity of 
targeted genes in living cells. Double-stranded RNAs with sequence complementary 
to a gene of interest are introduced into the cells, leading to inhibition or reduction 
of targeted gene expression via sequence-specific degradation or translational 
interference of mRNA transcripts [129,130]. In mammalian cells, either synthetic 
siRNAs or vector-based short hairpin RNAs (shRNA) can be used for gene 
knockdown. RNAi is also widely used in high-throughput screens. High-throughput 
RNAi screening is a powerful tool for identification of genes associated with a 
given pathway or specific biological loss-of function phenotypes [129,130]. In 
paper I, we have used the RNAi library targeting human DUBs to search for new 
regulators in the canonical Wnt signaling pathway.  
            
3.2 Bioinformatics 
 
Bioinformatics is a technique that combine computer technology with biology 
science to gather, store and integrate biological data such as nucleic acid, protein 
sequences, structures, functions, pathways and genetic interactions [131]. One of 
the important applications of bioinformatics is the sequence analysis. The 
advancement of sequencing technologies in the past decade has made it possible to 
rapidly sequence hundred of genomes from bacteria to humans. However, much of 
the sequence data is uncharacterized, and many genes encode proteins of unknown 
function. Sequence analysis is an effective tool to predict the function of 
unidentified sequence by means of finding homologous domains or proteins with 
conserved structural features [131-133]. In paper III and IV, we have used sequence 
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analysis method to identify DUBs with transmembrane domain and the SIAH 
interacting motif presented in USP19.  
 
 
3.3 Yeast two-hybrid screens 
 
 Yeast two-hybrid screen is a technique that detects physical interactions between 
two proteins. The technique is based on the activation of a reporter gene by binding 
of a transcription factor to the activating sequence. The transcription factor consists 
of two domains, the DNA binding domain and the activating domain. The DNA 
binding domain is responsible for the binding to a specific DNA sequence. The 
activating domain is responsible for the assembly of proteins required for 
transcription. In this screen, a GAL4 transcription factor is split into two separate 
parts. A protein of interest is fused with a GAL4 DNA-binding domain and 
transformed in yeast host cells generating the “bait”. A cDNA library of clones that 
are fused to the GAL4 activation domain carried in yeast cells are called “prey”. 
Only when the prey and the bait form protein-protein interaction, the down-stream 
reporter gene will be activated [134,135]. In paper II and V, we have used yeast 
two-hybrid technique to identify interacting partners of USP4 and USP19.  
 
 
3.4 Co-Immunoprecipitation  
 
Co-immunoprecipitation is a technique to identify protein-protein interactions. An 
antibody to the protein of interest is added to a cell lysate. Then protein-G coupled 
sepharose beads are used to capture the antibody-protein complex. These protein 
complexes can be analyzed by techniques like western blot to identify the binding 
partners [136,137]. 
 
 
3.5 GST pull-down assay 
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The GST pull-down assay is an in vitro technique to determine physical interaction 
between proteins.It can be used to identify direct protein interactions which can not 
be achieved by Co-immunoprecipitation.  A glutathione S-transferase (GST) tag is 
commonly fused to the protein of interest. GST-fusion proteins can be produced in 
Escherichia coli as bait. Glutathione-Agarose beads are used to pull down the GST-
protein complex. These protein complexes can be analyzed by technique like 
western blot to identify protein binding partners.  [138-140].  
 
3.6 Western blot 
 
Western blot is a widely used analytical technique to detect specific proteins in a 
given sample. SDS-PAGE is used to separate proteins according to the length and 
charge of the polypeptide. The proteins are then transferred to membranes and 
specific antibodies are used to detect the protein of interest [141,142]. 
 
 
3.7 Fluorescence microscopy 
 
Fluorescence microscopy is a powerful tool for study of protein localization and 
interactions. Target-specific fluorescent probes or labeled antibodies were used in 
fixed cells. The fluorescence microscopy permits the visualization of florescence in 
focused area, creating image with single or multi-colors [143,144].   
 
3.8 Real-Time PCR  
 
Real-Time PCR (qPCR) is a technique based on PCR. It can amplify and quantify 
targeted DNA sequence simultaneously. For more specific DNA sequences in a 
sample, Real-Time PCR enables both detection and quantification Real time PCR is 
based on the detection of the increase of fluorescence produced by reporter 
molecules that bind to double-stranded DNA or sequence specific probes, as 
proportional to the increase of DNA [145,146].  
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4 Results and Discussion 
 
4.1 Paper I 
 
The canonical Wnt-signaling is highly conserved and regulates a vast array of 
cellular process such as stem cell maintenance, tissue polarity, cell proliferation and 
movements [90]. Ubiquitination plays important roles in regulating this pathway. A 
lot of attention has been paid to the regulatory role of E3 ubiquitin ligases but very 
little is known on the enzymes that reverse the ubiquitination process. To this end, 
we have used an RNAi library targeting the family of DUBs to screen the canonical 
Wnt-signaling pathway for potential new regulators. 
 
In the screening, we identified USP4 as regulator of the canonical Wnt pathway. 
We have shown that USP4 knock-down increased Wnt signaling in cells where the 
pathway is activated either by mutations in APC (SW480 cells), by transfection of 
constitutively active β-catenin or by co-expression of the physiological Wnt1 ligand. 
To search for potential USP4 interacting partners and the mechanism behind, we 
performed a set of co-immunoprecipitation experiments and found that USP4 
interacts with two components of the Wnt pathway, the transcription factor TCF4 
and the Nemo like kinase (Nlk). We have demonstrated that overexpression of a 
catalytically active Nlk promotes nuclear accumulation of USP4. Moreover, USP4 
interacts with a post-translationally modified form of TCF4 that appears to be a 
substrate of USP4 DUB activity. Taken together, our data identified USP4 as a 
negative regulator of Wnt pathway. It is likely that USP4 regulates this pathway by 
going into the nucleus, interfering with the TCF4 transcription regulatory 
complexes by deubiquitinating TCF4.  
 
The result from this paper suggest that modulation of USP4 expression may provide 
a new means to interfere with canonical Wnt signaling in a variety of physiological 
and pathological conditions. 
 
 
  
26 
4.2 Paper II 
 
To further explore the functions of USP4 and to identify its interacting partners, we 
performed a yeast-two hybrid screen using as bait the N-terminal domain of USP4. 
The C-terminal DUB domain was excluded since it is relatively conserved and also 
presented in many other DUBs. The most striking interaction identified was with 
the proteasome subunit S9 that resides in the 19S RP. To confirm the interaction, 
we performed GST-pull down and in vitro binding experiments. Co- 
immunoprecipitation assays from cell lysates of transfected cells were performed to 
confirm the interaction in vivo. The binding to the proteasome subunit S9 suggests 
that USP4 might associate with 26S proteasome. We confirmed the USP4-26S 
proteasome association by co-immunoprecipitation assays.  
 
Many proteins associate with the proteasome via a UBL domain, one of the best-
characterized proteasome-interaction motif. More and more evidence supports a 
role of UBL domains in regulating the activity, specificity or interactions of several 
DUBs [147,148]. Two DUBs USP14 and UCH37, are known to interact with the 
proteasome via internal UBL domains. Here we identified USP4 as a third 
proteasome-interacting DUB. There are two UBL domains in USP4, one embedded 
in the catalytic site that has autoregulatory functions [81,148], and an N-terminal 
UBL domain of unknown functions. In order to test whether the UBL domain in 
USP4 is responsible for the binding to the proteasome we made several truncations/ 
deletions of USP4 constructs and tested their binding to S9 in GST-pull down 
assays. We have found the N-terminal domain of USP4 is responsible for the 
binding to S9. This interaction is specific for USP4 and does not involve a 
conventional UBL-binding domain on S9. The functional significance of the 
interaction between USP4 and S9 remains to be investigated. USP14 and UCH37 
associate with S1 and ADRM respectively and they dock close to the ubiquitinated 
substrate [28,65]. Their enzymatic activity is dramatically increased upon 
interaction with the proteasome [51,64], which is likely to restrict their activities to 
the site where it is needed. Unlike these DUBs, the activity of USP4 was not 
affected in the presence of S9, suggesting that USP4 is active also in the absence of 
the proteasome and therefore unlikely to be indiscriminately directed to all 
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ubiquitinated proteasomal substrates. Compared to other DUBs, the site of 
interaction of USP4 also suggests a different function. The S9 subunit was recently 
shown to serve as a molecular clamp that holds the proteasome core and the 
regulatory particle together [47]. USP4 may play a role in maturation or 
maintenance of the 26S proteasome complex, or in regulation the turn over of 
specific substrates.  
 
 
4.3 Paper III 
 
Ubiquitination of membrane proteins controls cellular events such as endocytosis, 
and membrane trafficking [149]. While a number of ubiquitin conjugating enzymes 
and ubiquitin ligases are known to reside in membranes, where they act as 
important regulators, less is known about the regulatory function of ubiquitin 
deconjugation in the same processes. To this end, we have used a bioinformatics 
approach to screen human DUB sequences for putative transmembrane domains and 
identified three candidates: USP48, USP30 and USP19. USP30 was shown to be a 
mitochondria-associated protein while USP48 is unlikely to be associated with 
membranes since the putative transmembrane domain overlaps with the DUB active 
site. We decided therefore to focus on USP19, previously known to be specifically 
regulated during muscle atrophy [82].   
           
We have functionally characterized USP19 and shown that it is anchored to the ER 
membrane via its C-terminal transmembrane domain. Based on the ER localization 
of USP19, we hypothesized it might be part of UPR and therefore regulated during 
ER stress. To test this possibility, we induced ER stress and measured USP19 
mRNA level by qPCR. Indeed USP19 mRNA was elevated more than two fold 
upon treatment with ER stress inducing agent. The ER localization and the 
upregulation after ER stress suggest that USP19 might function in ERAD. To test 
this possibility, we have examined the turn over of two ERAD substrates 
CFTRΔ508 and TCRα in the presence of USP19. We have shown that USP19 
interacts with CFTRΔ508 and TCRα and overexpression of USP19 stabilized both 
substrates. The presence of two CS/p23 domains is likely to be important for 
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USP19 function since a catalytic mutant USP19 could stabilize TCRα as well. 
Through the CS/p23 domain, USP19 may promote protein folding by interacting 
with HSP90 or it may act as an independent chaperone. This activity of USP19 
might be important for the rescue of proteins that needed to survive 
retrotranslocation.  
 
USP19 is the first example of a membrane-anchored DUB involved in the turnover 
of ERAD substrates.  
 
 
4.4 Paper IV 
 
In order to learn more about the function of USP19 and to identify its interacting 
partners, we have performed a yeast-two hybrid screen. As bait, we used the first 
495 amino acids of the N-terminus of USP19 that excludes the relatively conserved 
USP homology region. More than 50% of the hits in the screen were the ubiquitin 
ligases SIAH1 and SIAH2. 
 
SIAH1 and SIAH2 are highly conserved RING-type-E3 ubiquitin ligases that 
regulate a variety of signaling pathways and stress-related cellular events. We have 
first confirmed that USP19 is an interacting partner of both SIAH1 and SIAH2 
independently of both DUB and ligase activity. Next we set out to investigate the 
functional outcome of this interaction. Our results demonstrated that SIAH can 
ubiquitinate USP19 and promote its proteasomal degradation. USP19 does not seem 
to have a comparably strong effect on SIAH, which excludes a simple regulatory 
loop where the two enzymes could reciprocally regulate their stability. It is 
noteworthy that only some of the isoforms of USP19 expressed in cells interact with 
SIAH, suggesting the interaction may selectively affect some of the function of 
USP19.   
 
  Several SIAH interacting proteins contain a conserved RPVAxVxPxxR motif that 
functions as a degradation signal [150]. To investigate whether such region is 
present in USP19, we performed multiple sequence alignments with some known 
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SIAH interacting proteins. We have found that in USP19 contains a SIAH binding 
motif characterized by the presence of a fully conserved core VxP motif flanked by 
conserved basic residues. We further confirmed the predicted SIAH interacting 
motif by showing that deletion of the motif, or mutation of key residues, abolish its 
interaction with SIAH.  
 
In addition to SIAH, we have identified other USP19 binding partners in our yeast-
two hybrid screen including Filamin A, an actin binding protein with multiple 
cellular functions, and the E3 ligase RING2. This adds to the list of USP19 
interacting E3 ligases including previous reported KPC-1, XIAP, c-IAP1 and c-
IAP2 [84,85]. Taken together, the identification of several E3 ligases as binding 
partner, and in some cases substrates, of USP19 underlines the potential 
involvement of this DUB in a broad variety of ubiquitin-related cellular processes. 
 
 
4.5 Paper V 
 
The interaction with the hypoxia pathway components SIAH1 and SIAH2 suggests 
that USP19 may participate in the regulation of the response to hypoxia. To test 
whether USP19 could interact with additional components in the hypoxia pathway, 
we performed a set of co-immunoprecipitation experiments and found that USP19 
specifically interacts with HIF-1α. We further mapped the interacting region to the 
PAS and bHLH domains in the N-terminal of HIF-1α.  
 
USP19 can rescue c-IAP and ERAD substrates from proteasomal degradation 
[85,89]. For this reason, we tested whether USP19 can rescue HIF-1α from 
degradation. The result demonstrated that both USP19 and a catalytic inactive 
mutant rescue HIF-1α from degradation. The effect was reproduced in different cell 
lines, suggesting that it is not cell type specific. Based on these results, we set out to 
test whether USP19 was involved in the regulation of the cellular response to 
hypoxia. The knockdown studies demonstrated that, in the absence of USP19, HIF-
1α is continuously degraded by the proteasome. Furthermore, the HIF-1α 
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transcriptional response to hypoxia is significantly reduced in USP19 knockdown 
cells.  
 
Non-catalytic functions of DUBs are not rare and have recently emerged as an 
important way for these enzymes to perform their function [151,152]. USP19 may 
non-catalytically regulate HIF-1α stability by means of protein interactions or 
through competitive binding with additional partners. The N-terminal PAS and 
bHLH domains of HIF-1α are responsible for the interaction with USP19. Although 
this region is typically involved in DNA binding and dimerization with HIF-β, other 
interactions taking place here include the molecular chaperone HSP90 and Rack1 
that are associated with the O2-independent regulation of HIF-1α and the 
minichromosome maintenance protein (MCM7) that is involved in O2-dependent 
regulation [115].  Our data suggest that USP19 may be part of these regulatory 
protein complexes.  
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5 Concluding Remarks 
 
 
The overall aim of the studies presented in this thesis was to investigate the function 
of selected DUBs in the regulation of disease-relevant cellular functions. To this 
end, we have used a combination of bioinformatics and cell biology techniques, 
which allowed us not only to identify protein-protein interaction but also to 
investigate the role of DUBs in different molecular signaling pathways.  
 
In paper I and II, we have identified USP4 as a negative regulator of the Wnt 
pathway that modulates the ubiquitination of TCF4. We also found that USP4 
associates with the 26S proteasome via its N-terminal UBL domain. However, the 
functional significance of this interaction remains unclear. For example it is not 
known whether USP4 may affects the activity of the proteasome, or whether USP4 
might have a role in proteasome assembly.  
 
In paper III we have shown that USP19 is a DUB anchored to the ER membrane. 
USP19 is induced during ER stress and can rescue ERAD substrates from 
proteasomal degradation. In papers IV and V we further identified the ubiquitin 
ligases SIAH1 and SIAH2 and the transcription factor HIF-1α as USP19 interaction 
partners. USP19 regulates HIF-1α stability and is necessary for the appropriate 
cellular response to hypoxia. However, the mechanism of this regulation remains 
unclear. We have shown that SIAH regulates the stability of USP19. Since they 
both control the turnover of the key player of the hypoxia response, HIF-1α, it 
would be interesting to test how this interaction contributes to the fine-tuning of the 
hypoxic response.  
 
We have shown that USP19 is involved in ER stress, and other studies have 
documented the possible involvement of USP19 in the response to stress in rat 
skeletal muscles and regulation of apoptosis through rescue of c-IAP [82,85]. Taken 
together these findings suggest that USP19 may play a cytoprotective role and 
contribute to the capacity of cells to adapt to different source of stress. In order to 
have a better understanding of this DUB, future work should be done to identify 
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additional interacting partners and to reveal new functions in ubiquitin-regulated 
cellular processes. It is also worth noting that twelve slice variants of USP19 have 
been identified, only three of which are membrane associated. We have shown that 
membrane association is critical for the function of USP19 in ERAD but is 
dispensable for their regulatory role in the hypoxic response. Furthermore, only 
some of the splice variants have the ability to interact with HIF-1α and SIAH. Thus, 
work aiming to understand the specific functions, tissue expression and subcellular 
localization of the different splice variants of USP19 is likely to yield important 
insights on the activity of this DUB in different signaling pathways  
 
Collectively, the work described in this thesis has generated new knowledge 
regarding DUB interacting partners and their function in regulating cellular 
signaling pathways.  
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